



(12) Translation of
European patent specification

(11) NO/EP 2429524 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 9/08 (2006.01)

A61K 9/48 (2006.01)

A61K 9/00 (2006.01)

A61K 31/5377 (2006.01)

A61K 9/14 (2006.01)

A61P 35/02 (2006.01)

A61K 9/16 (2006.01)

Norwegian Industrial Property Office

- (45) Translation Published 2020.03.23
- (80) Date of The European Patent Office Publication of the Granted Patent 2020.01.15
- (86) European Application Nr. 10719218.9
- (86) European Filing Date 2010.05.14
- (87) The European Application's Publication Date 2012.03.21
- (30) Priority 2009.05.14, US, 178472 P
2009.09.18, US, 243977 P
- (84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
- (73) Proprietor Ambit Biosciences Corporation, 11080 Roselle Street San Diego, CA 92121, USA
- (72) Inventor CORRINGHAM, Robert E., 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA
O'DONNELL, Patrick B., 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA
JAMES, Joyce K., 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA
- (74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge
-

(54) Title **Spray dried formulation of AC220**

(56) References


Cited:

WO-A1-2014/055397, WO-A1-2009/061446, WO-A1-2010/111172, WO-A2-2007/109120
CORTES JORGE E ET AL: "Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 16 November 2008 (2008-11-16), pages 284-285, XP009135854 ISSN: 0006-4971
CORTES JORGE ET AL: "Human pharmacokinetics of AC220, a potent and selective class III receptor tyrosine kinase inhibitor" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11, suppl, 1 November 2007 (2007-11-01), page 477A, XP009135857 ISSN: 0006-4971
JAMES JOYCE ET AL: "Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3" BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 November 2008 (2008-11-01), page 912, XP009135855 ISSN: 0006-4971

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Spraytørket farmasøytisk sammensetning omfattende en forbindelse med formel I,



5 eller et farmasøytisk akseptabelt salt eller solvat derav, og hydroksypropyl-p-syklodekstrin.

2. Farmasøytisk sammensetning ifølge krav 1, hvor forbindelsen er et dihydrokloridsalt.

10

3. Farmasøytisk sammensetning ifølge krav 1, hvor solvatet er et metanolsolvat.

4. Farmasøytisk sammensetning ifølge krav 1, omfattende en forbindelsen med formel I og hydroksypropyl-p-syklodekstrin i et forhold på ca. 1:10 basert på vekt.

15

5. Farmasøytisk sammensetning ifølge krav 1, hvor sammensetningen er formulert for administrering av en enkelt dose.

6. Farmasøytisk sammensetning ifølge krav 1, hvor sammensetningen er formulert for oral administrering.

20